MX2023005675A - Agentes farmacológicos para tratar afecciones del ojo. - Google Patents
Agentes farmacológicos para tratar afecciones del ojo.Info
- Publication number
- MX2023005675A MX2023005675A MX2023005675A MX2023005675A MX2023005675A MX 2023005675 A MX2023005675 A MX 2023005675A MX 2023005675 A MX2023005675 A MX 2023005675A MX 2023005675 A MX2023005675 A MX 2023005675A MX 2023005675 A MX2023005675 A MX 2023005675A
- Authority
- MX
- Mexico
- Prior art keywords
- eye
- pharmacological agents
- treating conditions
- reducing
- treating
- Prior art date
Links
- 239000002831 pharmacologic agent Substances 0.000 title 1
- 108010071690 Prealbumin Proteins 0.000 abstract 2
- 102000009190 Transthyretin Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000001491 myopia Diseases 0.000 abstract 1
- 230000004379 myopia Effects 0.000 abstract 1
- 201000010041 presbyopia Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113691P | 2020-11-13 | 2020-11-13 | |
| US202163215818P | 2021-06-28 | 2021-06-28 | |
| PCT/US2021/072405 WO2022104383A1 (en) | 2020-11-13 | 2021-11-15 | Pharmacological agents for treating conditions of the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005675A true MX2023005675A (es) | 2023-07-31 |
Family
ID=81601792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005675A MX2023005675A (es) | 2020-11-13 | 2021-11-15 | Agentes farmacológicos para tratar afecciones del ojo. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240000812A1 (enExample) |
| EP (1) | EP4243798A4 (enExample) |
| JP (1) | JP2023549533A (enExample) |
| CA (1) | CA3202073A1 (enExample) |
| MX (1) | MX2023005675A (enExample) |
| WO (1) | WO2022104383A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872236B2 (en) | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| WO2025090994A1 (en) * | 2023-10-26 | 2025-05-01 | Plex Pharmaceuticals, Inc. | Compositions for treating cataracts and/or presbyopia eye diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE439863T1 (de) * | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| JP6068484B2 (ja) * | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダSom Innovation Biotech, S.L. | トランスサイレチン関連アミロイドーシスの新規療法 |
| WO2013098416A2 (fr) * | 2011-12-30 | 2013-07-04 | Ecole Nationale Superieure De Chimie De Clermont Ferrand | Composes anti-douleur |
| WO2014164667A1 (en) * | 2013-03-11 | 2014-10-09 | Georgetown University | Dengue and west nile virus protease inhibitors |
| US20160317474A1 (en) * | 2013-12-18 | 2016-11-03 | Emory University | Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects |
| US11872236B2 (en) * | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| EP3683618A1 (en) * | 2019-01-21 | 2020-07-22 | Essilor International (Compagnie Generale D'optique) | System and method for demonstrating an optical disorder |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| JP2024520837A (ja) * | 2021-06-08 | 2024-05-24 | プレックビジョン、バイオテクノロジーズ、リミテッド | ダニの抑制又は滅殺及び眼球乾燥症の治療におけるcyp450阻害剤の使用 |
-
2021
- 2021-11-15 WO PCT/US2021/072405 patent/WO2022104383A1/en not_active Ceased
- 2021-11-15 US US18/037,021 patent/US20240000812A1/en active Pending
- 2021-11-15 CA CA3202073A patent/CA3202073A1/en active Pending
- 2021-11-15 EP EP21893092.3A patent/EP4243798A4/en active Pending
- 2021-11-15 JP JP2023528761A patent/JP2023549533A/ja active Pending
- 2021-11-15 MX MX2023005675A patent/MX2023005675A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4243798A1 (en) | 2023-09-20 |
| WO2022104383A1 (en) | 2022-05-19 |
| JP2023549533A (ja) | 2023-11-27 |
| CA3202073A1 (en) | 2022-05-19 |
| US20240000812A1 (en) | 2024-01-04 |
| EP4243798A4 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bullimore et al. | The risks and benefits of myopia control | |
| Shunmugam et al. | Giant retinal tears | |
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| MX2024015479A (es) | Moduladores de la via de respuesta integrada al estres | |
| PH12023550153A1 (en) | Inhibitors of complement factors and uses thereof | |
| CR20210395A (es) | Moduladores de la expresión de hsd17b13 | |
| UY30061A1 (es) | Inhibición de hif 1a mediada por arni para el tratamiento de la angiogénesis ocular | |
| MX2024001713A (es) | Metodos y composiciones para tratar la apnea del sue?o. | |
| MX2022009243A (es) | Moduladores de la via de respuesta integrada al estres. | |
| MX2020012980A (es) | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. | |
| PH12020551995A1 (en) | Modulator of apol1 expression | |
| WO2019195761A3 (en) | Pharmacological agents for treating ocular diseases | |
| WO2019140372A3 (en) | Methods of treatment by inhibition of bfl 1 | |
| MX2023006578A (es) | Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas. | |
| MX2021004280A (es) | Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. | |
| WO2007011875A3 (en) | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders | |
| MX2022009025A (es) | Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina. | |
| RU2010116859A (ru) | ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА В ЛЕЧЕНИИ РАССЕЯННОГО СКЛЕРОЗА И АУТОИММУННОГО МИЕЛИТА | |
| Wang et al. | Comparative study of femtosecond laser‐assisted cataract surgery and conventional phacoemulsification in vitrectomized eyes | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
| MX2023013504A (es) | Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1). | |
| MX2025013710A (es) | Composiciones para mejorar el sueño y métodos de uso | |
| MX2021014682A (es) | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. | |
| WO2008048675A3 (en) | Treatment for age-related macular degeneration and other diseases of the eye | |
| MX2022013927A (es) | Composiciones y metodos para tratar la epilepsia. |